2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Journal of the American College of Cardiology

Volumn 70, Issue 24, 2017, Pages 3042-3067

  Tomaselli, Gordon F ^a   Mahaffey, Kenneth W ^a   Cuker, Adam ^a   Dobesh, Paul P ^a   Doherty, John U ^a   Eikelboom, John W ^a   Florido, Roberta ^a   Hucker, William ^a   Mehran, Roxana ^a   Messé, Steven R ^a   Pollack, Charles V ^a   Rodriguez, Fatima ^a   Sarode, Ravindra ^a   Siegal, Deborah ^a   Wiggins, Barbara S ^a  

^a NONE

Author keywords

ACC Expert Consensus Decision Pathway; atrial fibrillation; deep vein thrombosis; factor II; factor X; gastrointestinal bleeding; intracranial hemorrhage; vitamin K

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; APIXABAN; CANGRELOR; CIRAPARANTAG; CLOPIDOGREL; DABIGATRAN; DILTIAZEM; EDOXABAN; HEMOGLOBIN; IDARUCIZUMAB; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; RIVAROXABAN; TICAGRELOR; VERAPAMIL; WARFARIN;

ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL DECISION MAKING; CONSENSUS; DISEASE SEVERITY; DOCTOR PATIENT RELATION; ERYTHROCYTE; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TECHNIQUE; MEASUREMENT; MEDICAL DECISION MAKING; MEDICAL EXPERT; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; ADVISORY COMMITTEE; ATRIAL FIBRILLATION; CARDIOLOGY; CHEMICALLY INDUCED; COMPLICATION; DECISION MAKING; DISEASE MANAGEMENT; MEDICAL SOCIETY; ORAL DRUG ADMINISTRATION; UNITED STATES; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ADVISORY COMMITTEES; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; CONSENSUS; DECISION MAKING; DISEASE MANAGEMENT; HEMORRHAGE; HUMANS; SOCIETIES, MEDICAL; UNITED STATES; VENOUS THROMBOSIS;

EID: 85036512946     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.09.1085     Document Type: Article

References (110)

1. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics–2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
2. Huang, W., Goldberg, R.J., Anderson, F.A., et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med 127 (2014), 829–839.e5.
3. Alotaibi, G.S., Wu, C., Senthilselvan, A., et al. Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study. Am J Med 129 (2016), 879.e19–879.e25.
4. Barnes, G.D., Lucas, E., Alexander, G.C., et al. National trends in ambulatory oral anticoagulant use. Am J Med 128 (2015), 1300–1305.e2.
5. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
6. Yao, X., Abraham, N.S., Alexander, G.C., et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc, 5, 2016, e003074.
7. Glund, S., Stangier, J., Schmohl, M., et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386 (2015), 680–690.
8. Ruff, C.T., Giugliano, R.P., Antman, E.M., Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents. Circulation 134 (2016), 248–261.
9. Schulman, S., Angeras, U., Bergqvist, D., et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8 (2010), 202–204.
10. Doherty, J.U., Gluckman, T.J., Hucker, W.J., et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 69 (2017), 871–898.
11. Sevransky, J., Clinical assessment of hemodynamically unstable patients. Curr Opin Crit Care 15 (2009), 234–238.
12. Smilowitz, N.R., Oberweis, B.S., Nukala, S., et al. Association between anemia, bleeding, and transfusion with long-term mortality following noncardiac surgery. Am J Med 129 (2016), 315–323.e2.
13. Fakhry, S.M., Fata, P., How low is too low? Cardiac risks with anemia. Crit Care 8:Suppl 2 (2004), S11–S14.
14. Damluji, A.A., Macon, C., Fox, A., et al. The association between in-hospital hemoglobin changes, cardiovascular events, and mortality in acute decompensated heart failure: results from the ESCAPE trial. Int J Cardiol 222 (2016), 531–537.
15. Cuker, A., Siegal, D., Monitoring and reversal of direct oral anticoagulants. Hematology Am Soc Hematol Educ Program 2015 (2015), 117–124.
16. Cuker, A., Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 41 (2016), 241–247.
17. Levy, J.H., Ageno, W., Chan, N.C., et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14 (2016), 623–627.
18. Samuelson, B.T., Cuker, A., Siegal, D.M., et al. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 151 (2017), 127–138.
19. Cuker, A., Siegal, D.M., Crowther, M.A., et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64 (2014), 1128–1139.
20. Cuker, A., Husseinzadeh, H., Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39 (2015), 288–294.
21. Baradarian, R., Ramdhaney, S., Chapalamadugu, R., et al. Early intensive resuscitation of patients with upper gastrointestinal bleeding decreases mortality. Am J Gastroenterol 99 (2004), 619–622.
22. Spoerke, N., Michalek, J., Schreiber, M., et al. Crystalloid resuscitation improves survival in trauma patients receiving low ratios of fresh frozen plasma to packed red blood cells. J Trauma 71 (2011), S380–S383.
23. Perel, P., Roberts, I., Ker, K., Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev, 2, 2013, CD000567.
24. Young, P., Bailey, M., Beasley, R., et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA 314 (2015), 1701–1710.
25. Villanueva, C., Colomo, A., Bosch, A., et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 368 (2013), 11–21.
26. Carson, J.L., Guyatt, G., Heddle, N.M., et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 316 (2016), 2025–2035.
27. Tobian, A.A., Heddle, N.M., Wiegmann, T.L., et al. Red blood cell transfusion: 2016 clinical practice guidelines from AABB. Transfusion 56 (2016), 2627–2630.
28. Razzaghi, A., Barkun, A.N., Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. J Clin Gastroenterol 46 (2012), 482–486.
29. Contreras, M., Consensus conference on platelet transfusion. Final statement. Blood Rev 12 (1998), 239–240.
30. Dzik, W.H., Blajchman, M.A., Fergusson, D., et al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products—massive transfusion consensus conference 2011: report of the panel. Crit Care, 15, 2011, 242.
31. Holcomb, J.B., Tilley, B.C., Baraniuk, S., et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313 (2015), 471–482.
32. Shakur, H. R.I., Bautista, R., Caballero, J., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376 (2010), 23–32.
33. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
34. Mannucci, P.M., Remuzzi, G., Pusineri, F., et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308 (1983), 8–12.
35. Janson, P.A., Jubelirer, S.J., Weinstein, M.J., et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303 (1980), 1318–1322.
36. Hedges, S.J., Dehoney, S.B., Hooper, J.S., et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 3 (2007), 138–153.
37. Weeder, P.D., Porte, R.J., Lisman, T., Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev 28 (2014), 107–113.
38. Casutt, M., Konrad, C., Schuepfer, G., Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM. Anaesthesist 61 (2012), 948–953.
39. Xu, Y., Wu, W., Wang, L., et al. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis 24 (2013), 332–338.
40. Eller, T., Busse, J., Dittrich, M., et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med 52 (2014), 835–844.
41. Shah, N.L., Intagliata, N.M., Northup, P.G., et al. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol 11 (2014), 675–682.
42. Batchelor, J.S., Grayson, A., A meta-analysis to determine the effect on survival of platelet transfusions in patients with either spontaneous or traumatic antiplatelet medication-associated intracranial haemorrhage. BMJ Open, 2, 2012, e000588.
43. Nishijima, D.K., Zehtabchi, S., Berrong, J., et al. Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review. J Trauma Acute Care Surg 72 (2012), 1658–1663.
44. Baharoglu, M.I., Cordonnier, C., Salman, R.A.-S., et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387 (2016), 2605–2613.
45. Miller, J., Lieberman, L., Nahab, B., et al. Delayed intracranial hemorrhage in the anticoagulated patient: A systematic review. J Trauma Acute Care Surg 79 (2015), 310–313.
46. Schoonman, G.G., Bakker, D.P., Jellema, K., Low risk of late intracranial complications in mild traumatic brain injury patients using oral anticoagulation after an initial normal brain computed tomography scan: education instead of hospitalization. Eur J Neurol 21 (2014), 1021–1025.
47. Heidbuchel, H., Verhamme, P., Alings, M., et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 27 (2017), 2137–2149.
48. Nutescu, E.A., Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm 70 (2013), S3–S11.
49. Bayer Healthcare JP, Inc. Xarelto prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf. Accessed March 14, 2016.
50. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022512s017lbl.pdf. Accessed March 14, 2016.
51. Chang, M., Yu, Z., Shenker, A., et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 56 (2016), 637–645.
52. Dias, C., Moore, K.T., Murphy, J., et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 43 (2016), 229–236.
53. Kubitza, D., Becka, M., Mueck, W., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70 (2010), 703–712.
54. Parasrampuria, D.A., Marbury, T., Matsushima, N., et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 113 (2015), 719–727.
55. Ridout, G., de la Motte, S., Niemczyk, S., et al. Effect of renal function on edoxaban pharmacokinetics and on population PK model. J Clin Pharmacol 49 (2009), 1091–1130.
56. Chai-Adisaksopha, C., Hillis, C., Siegal, D.M., et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 116 (2016), 879–890.
57. Britt, R.B., Brown, J.N., Characterizing the severe reactions of parenteral vitamin K1. Clin Appl Thromb Hemost, 2016 1076029616674825.
58. Sarode, R., Milling, T.J. Jr., Refaai, M.A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128 (2013), 1234–1243.
59. Milling, T.J. Jr., Refaai, M.A., Sarode, R., et al. Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med 23 (2016), 466–475.
60. Pollack, C.V. Jr., Reilly, P.A., Bernstein, R., et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 114 (2015), 198–205.
61. van Ryn, J., Stangier, J., Haertter, S., et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103 (2010), 1116–1127.
62. Pollack, C.V. Jr., Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.
63. Pollack, C.V. Jr., Reilly, P.A., van Ryn, J., et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 377 (2017), 431–441.
64. Pollack CV Jr., Reilly PA, van Ryn J, et al. Updated results of the RE-VERSE AD™ study: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. Paper presented at: American Heart Association Scientific Sessions 2016; New Orleans, LA; November 12–16, 2016.
65. Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124 (2011), 1573–1579.
66. Marlu, R., Hodaj, E., Paris, A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108 (2012), 217–224.
67. Zhou, W., Schwarting, S., Illanes, S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42 (2011), 3594–3599.
68. Pragst, I., Zeitler, S.H., Doerr, B., et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 10 (2012), 1841–1848.
69. Hoffman, M., Volovyk, Z., Monroe, D.M., Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. Anesthesiology 122 (2015), 353–362.
70. Lindahl, T.L., Wallstedt, M., Gustafsson, K.M., et al. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res 135 (2015), 544–547.
71. Wong, H., Keeling, D., Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Br J Haematol 166 (2014), 152–153.
72. Schulman, S., Ritchie, B., Goy, J.K., et al. Activated prothrombin complex concentrate for dabigatran-associated bleeding. Br J Haematol 164 (2014), 308–310.
73. Stangier, J., Rathgen, K., Stahle, H., et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49 (2010), 259–268.
74. Crowther, M., Crowther, M.A., Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol 35 (2015), 1736–1745.
75. Siegal, D.M., Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39 (2015), 395–402.
76. Levi, M., Moore, K.T., Castillejos, C.F., et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 12 (2014), 1428–1436.
77. Zahir, H., Brown, K.S., Vandell, A.G., et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131 (2015), 82–90.
78. Baxter Healthcare Corporation. FEIBA NF (anti-inhibitor coagulant complex), nanofiltered and vapor heated. Available at: http://www.feiba.com/us/forms/feiba_nf_pi.pdf. Accessed February 12, 2017.
79. Dibu, J.R., Weimer, J.M., Ahrens, C., et al. The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care 24 (2016), 413–419.
80. Lu, G., DeGuzman, F.R., Hollenbach, S.J., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19 (2013), 446–451.
81. Siegal, D.M., Curnutte, J.T., Connolly, S.J., et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373 (2015), 2413–2424.
82. Connolly, S.J., Milling, T.J. Jr., Eikelboom, J.W., et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375 (2016), 1131–1141.
83. Ansell, J.E., Bakhru, S.H., Laulicht, B.E., et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371 (2014), 2141–2142.
84. Ansell, J.E., Bakhru, S.H., Laulicht, B.E., et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 117 (2017), 238–245.
85. Hernandez, I., Zhang, Y., Brooks, M.M., et al. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke 48 (2017), 159–166.
86. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 (2017), 252–289.
87. Decousus, H., Leizorovicz, A., Parent, F., et al., for the Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 338 (1998), 409–415.
88. Mismetti, P., Laporte, S., Pellerin, O., et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA 313 (2015), 1627–1635.
89. Kearon, C., Akl, E.A., Ornelas, J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149 (2016), 315–352.
90. Hylek, E.M., Go, A.S., Chang, Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349 (2003), 1019–1026.
91. Hylek E. Best practices to balance stroke and bleeding risk in patients with AF. December 14, 2016. Available at: https://www.medscape.org/viewarticle/869761. CME; Accessed February 12, 2017.
92. Levine, G.N., Bates, E.R., Bittl, J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
93. Holbrook, A., Schulman, S., Witt, D.M., et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), e152S–e184S.
94. Gibson, C.M., Mehran, R., Bode, C., et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375 (2016), 2423–2434.
95. Chai-Adisaksopha, C., Hillis, C., Monreal, M., et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. a meta-analysis. Thromb Haemost 114 (2015), 819–825.
96. Majeed, A., Wallvik, N., Eriksson, J., et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost 117 (2017), 491–499.
97. Sengupta, N., Feuerstein, J.D., Patwardhan, V.R., et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 110 (2015), 328–335.
98. Qureshi, W., Mittal, C., Patsias, I., et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 113 (2014), 662–668.
99. Cervera, A., Amaro, S., Chamorro, A., Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 259 (2012), 212–224.
100. Hemphill, J.C. 3rd, Greenberg, S.M., Anderson, C.S., et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 46 (2015), 2032–2060.
101. Kuramatsu, J.B., Gerner, S.T., Schellinger, P.D., et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313 (2015), 824–836.
102. Milling, T.J. Jr., Spyropoulos, A.C., Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. Am J Med 129 (2016), S54–S63.
103. Witt, D.M., Delate, T., Hylek, E.M., et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thromb Res 132 (2013), 770–775.
104. Yung, D., Kapral, M.K., Asllani, E., et al. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol 28 (2012), 33–39.
105. Nielsen, P.B., Larsen, T.B., Skjoth, F., et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 132 (2015), 517–525.
106. Hawryluk, G.W., Austin, J.W., Furlan, J.C., et al. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 8 (2010), 1500–1508.
107. Nielsen, P.B., Larsen, T.B., Skjoth, F., et al. Outcomes associated With resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern Med 177 (2017), 563–570.
108. Murthy, S.B., Gupta, A., Merkler, A.E., et al. Restarting anticoagulant therapy after intracranial hemorrhage: A systematic review and meta-analysis. Stroke 48 (2017), 1594–1600.
109. Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
110. Douketis, J.D., Spyropoulos, A.C., Kaatz, S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.